A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation
C Li, X Wu, X Feng, Y He, H Liu, F Pei… - Blood, The Journal …, 2012 - ashpublications.org
We used a novel NF-08-TM transplant protocol based on intravenous busulfan,
cyclophosphamide, fludarabine, and thiotepa in 82 consecutive patients with β-thalassemia …
cyclophosphamide, fludarabine, and thiotepa in 82 consecutive patients with β-thalassemia …
[HTML][HTML] Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia …
A Ghavamzadeh, M Iravani, A Ashouri… - Biology of Blood and …, 2008 - Elsevier
Peripheral blood stem cell transplantation (PBSCT) has been extended to treating
hematologic disorders, but the benefits over bone marrow transplantation (BMT) still remain …
hematologic disorders, but the benefits over bone marrow transplantation (BMT) still remain …
[HTML][HTML] Unrelated donor peripheral blood stem cell transplantation for patients with β-thalassemia major based on a novel conditioning regimen
L Sun, N Wang, Y Chen, L Tang, C Xing, N Lu… - Biology of Blood and …, 2019 - Elsevier
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only available curative
treatment for patients with β-thalassemia major (β-TM). However, the problem of finding a …
treatment for patients with β-thalassemia major (β-TM). However, the problem of finding a …
Cyclosporine use in hematopoietic stem cell transplantation: pharmacokinetic approach
A Tafazoli - Immunotherapy, 2015 - Taylor & Francis
Cyclosporine is one of the most vital agents in the process of successful allogeneic
hematopoietic stem cell transplantation. Despite a long history and worldwide extent of …
hematopoietic stem cell transplantation. Despite a long history and worldwide extent of …
[HTML][HTML] Twenty years of experience on stem cell transplantation in Iran
A Ghavamzadeh, K Alimoghaddam… - Iranian Red Crescent …, 2013 - ncbi.nlm.nih.gov
Background Hematopoietic stem cell transplantation (HSCT) is a new window to therapy of
many diseases. From March 1991 through April 2011, a total of 3237 HSCT were performed …
many diseases. From March 1991 through April 2011, a total of 3237 HSCT were performed …
Dose-dependent inhibition of transporter-mediated hepatic uptake and biliary excretion of methotrexate by cyclosporine A in an isolated perfused rat liver model
R Parasrampuria, R Mehvar - Journal of pharmaceutical sciences, 2010 - Elsevier
Methotrexate (MTX) and cyclosporine (CyA) are coadministered in a number of diseases. In
this study, the effects of CyA on the hepatobiliary disposition of MTX were investigated in an …
this study, the effects of CyA on the hepatobiliary disposition of MTX were investigated in an …
Review of chronic graft-versus-host disease in children after allogeneic stem cell transplantation: nursing perspective
YM Liu, M Hockenberry - Journal of Pediatric Oncology …, 2011 - journals.sagepub.com
This review presents a summary of the research literature related to the incidence and risk
factors for chronic graft-versus-host disease in children following allogeneic hematopoietic …
factors for chronic graft-versus-host disease in children following allogeneic hematopoietic …
雷帕霉素治疗难治性广泛性慢性移植物抗宿主病
李旭东， 何易， 王东宁， 胡元， 王文文， 张祥忠， 林东军 - 中国组织工程研究, 2013 - cjter.com
背景: 难治性广泛性慢性移植物抗宿主病是异基因造血干细胞移植晚期的主要并发症,
目前一线治疗药物为糖皮质激素, 但对于糖皮质激素治疗无效或激素依赖的患者临床上尚缺乏 …
目前一线治疗药物为糖皮质激素, 但对于糖皮质激素治疗无效或激素依赖的患者临床上尚缺乏 …
[HTML][HTML] Evaluation of risk for graft-versus-host disease in children who receive less than the full doses of mini-dose methotrexate for graft-versus-host disease …
SK Yum, HY Choi, JW Lee, PS Jang… - Korean journal of …, 2013 - ncbi.nlm.nih.gov
Purpose The use of cyclosporine and mini-dose methotrexate (MTX) is a common strategy
for graft-versus-host disease (GVHD) prophylaxis in allogeneic transplants. We investigated …
for graft-versus-host disease (GVHD) prophylaxis in allogeneic transplants. We investigated …
[HTML][HTML] Methotrexate reduces the incidence of severe acute graft-versus-host disease without increasing the risk of relapse after reduced-intensity allogeneic stem …
S Vigouroux, R Tabrizi, C Melot, J Coiffard… - Biology of Blood and …, 2011 - Elsevier
Optimized prophylaxis against graft-versus-host disease (GVHD) after unrelated reduced-
intensity allogeneic transplantation when preceded by a conditioning regimen utilizing …
intensity allogeneic transplantation when preceded by a conditioning regimen utilizing …